Alirocumab administered every 2 or 4 weeks (Q2W or Q4W dosing regimen) significantly reduced low-density lipoprotein-cholesterol (LDL-C) levelsin paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), according to a study presented at ESC 2023.
A recent study provides further evidence to support the current recommendations for empirical intravenous treatment with gentamicin and ampicillin for febrile infants younger than 2 months with suspected urinary tract infection (UTI).
Treatment with deferasirox twice daily, compared with a once-daily regimen, results in significant improvements in the iron chelation efficacy and tolerability among transfusion-dependent paediatric beta-thalassaemia patients, a study has shown.
New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.